{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:45:53Z","timestamp":1793666753380,"version":"4.5.1"},"reference-count":30,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2023,3,21]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To report 5-year efficacy and safety of upadacitinib (UPA) in rheumatoid arthritis (RA) from the phase III long-term extension (LTE) of SELECT-NEXT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients on stable conventional synthetic disease-modifying antirheumatic drugs were randomized to UPA 15 mg once daily (QD), UPA 30 mg QD, or placebo for 12 weeks. Following this, placebo-randomized patients were switched to UPA 15 mg QD or UPA 30 mg QD in the LTE; UPA-randomized patients continued their original dose. Blinding remained until dose switching from UPA 30 mg QD to UPA 15 mg QD because of approval of UPA 15 mg QD; the earliest switch occurred at week 168. Efficacy (as observed) and treatment-emergent adverse events (TEAEs) are reported through 5 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 611 (92%) randomized patients entered the LTE; 271 (44%) discontinued the study drug by 5 years, primarily because of adverse events (16%). Clinical outcomes improved or were maintained at 5 years; 51% and 43% of patients achieved Clinical Disease Activity Index remission and 75% and 66% achieved Disease Activity Score in 28 joints based on C-reactive protein &lt; 2.6 among those initially randomized to UPA 15 mg QD and UPA 30 mg QD, respectively. Proportions of patients achieving \u2265 20%\/50%\/70% improvement in American College of Rheumatology criteria responses increased from week 60 through 5 years. Results were similar regardless of initial randomization to UPA or placebo. TEAEs, including TEAEs of special interest, were consistent with earlier analyses and other SELECT studies. Malignancies (excluding nonmelanoma skin cancer), major adverse cardiovascular events, and venous thromboembolic events were reported infrequently. No new safety signals were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The 5-year benefit-risk profile for UPA in RA remains favorable. (SELECT-NEXT; ClinicalTrials.gov:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02675426\">NCT02675426<\/jats:ext-link>)<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2023-1062","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T12:25:21Z","timestamp":1713183921000},"page":"663-672","source":"Crossref","is-referenced-by-count":8,"title":["Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R.","family":"Burmester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5932","authenticated-orcid":false,"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-7171","authenticated-orcid":false,"given":"John","family":"Tesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1945-9255","authenticated-orcid":false,"given":"Anna","family":"Shmagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2632-015X","authenticated-orcid":false,"given":"Heidi S.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-1310","authenticated-orcid":false,"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"2024070105201312000_51.7.663.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30173-8. PubMed PMID: 27156434."},{"key":"2024070105201312000_51.7.663.2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5114\/reum.2018.75523","article-title":"Cartilage and bone damage in rheumatoid arthritis","volume":"56","author":"Ostrowska","year":"2018","journal-title":"Reumatologia"},{"key":"2024070105201312000_51.7.663.3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24596"},{"key":"2024070105201312000_51.7.663.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2024070105201312000_51.7.663.5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"2024070105201312000_51.7.663.6","unstructured":"European Medicines Agency . Xeljanz (tofacitinib) summary of product characteristics. [Internet. Accessed May 2, 2024.] Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf"},{"key":"2024070105201312000_51.7.663.7","unstructured":"US Food and Drug Administration . Xeljanz (tofacitinib) highlights of prescribing information. [Internet. Accessed May 2, 2024.] Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/203214s028,208246s013,213082s003lbl.pdf"},{"key":"2024070105201312000_51.7.663.8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2024070105201312000_51.7.663.9","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2024070105201312000_51.7.663.10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002012"},{"key":"2024070105201312000_51.7.663.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31115-2"},{"key":"2024070105201312000_51.7.663.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"2024070105201312000_51.7.663.13","doi-asserted-by":"crossref","unstructured":"Burmester GR , Van den Bosch F , Bessette L , Long-term safety and efficacy of upadacitinib in patients with rheumatoid arthritis and an inadequate response to csDMARDs: results at 60 weeks [abstract]. Arthritis Rheumatol 2019:71 Suppl 10.","DOI":"10.1136\/annrheumdis-2019-eular.3082"},{"key":"2024070105201312000_51.7.663.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30419-2"},{"key":"2024070105201312000_51.7.663.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2024070105201312000_51.7.663.16","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2024070105201312000_51.7.663.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"2024070105201312000_51.7.663.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084459"},{"key":"2024070105201312000_51.7.663.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(05)80189-X"},{"key":"2024070105201312000_51.7.663.20","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"2024070105201312000_51.7.663.21","unstructured":"NCI . Common terminology criteria for adverse events (CTCAE), version 4.0. [Internet. Accessed May 8, 2024.] Available from: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf"},{"key":"2024070105201312000_51.7.663.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"2024070105201312000_51.7.663.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223916"},{"key":"2024070105201312000_51.7.663.24","unstructured":"U.S. Department of Health and Human Services . Guidance for industry drug-induced liver injury: premarketing clinical evaluation. [Internet. Accessed May 2, 2024.] Available from: https:\/\/www.fda.gov\/media\/116737\/download"},{"key":"2024070105201312000_51.7.663.25","unstructured":"Fleischmann R , Meerwein S , Charles-Schoeman C , Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biologic DMARDs: results through 5 years from the SELECT-BEYOND study [abstract]. Arthritis Rheumatol 2022;74 Suppl 9."},{"key":"2024070105201312000_51.7.663.26","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395"},{"key":"2024070105201312000_51.7.663.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171361"},{"key":"2024070105201312000_51.7.663.28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew329"},{"key":"2024070105201312000_51.7.663.29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40744-023-00621-6","article-title":"Malignancy in the upadacitinib clinical trials for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis","volume":"11","author":"Rubbert-Roth","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2024070105201312000_51.7.663.30","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-1062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T12:20:46Z","timestamp":1719836446000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-1062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.3899\/jrheum.2023-1062"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-1062","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}